[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nutraceuticals Research Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":99},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100609105","the-effectiveness-of-a-proprietary-ashwagandha-extract-on-menopausal-symptoms-a-three-arm-randomized-double-blinded-placebo-controlled-clinical-trial-100609105",false,"NCT07210229","The Effectiveness of a Proprietary Ashwagandha Extract on Menopausal Symptoms: A Three-Arm Randomized, Double-Blinded, Placebo Controlled Clinical Trial","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness and demonstrated ability to comply with all study procedures, as well as availability for the duration of the study\n* Baseline score of above-average menopause symptom levels on each of the patient reported scales: NRI-MSS (defined as 22+), the MRS scale (defined as 9+), AND 4+ on the MENQoL.\n* Confirmation of presence of hot flashes\n* Estridiol levels within the bottom 35% of normal ranges for their menstrual cycle phase (follicular\u002Fovulation\u002Fluteal) as established by laboratory reference range\n* Biological sex of female; gender identification of woman\n* Aged 40 to 55, inclusive\n* Good general health as evidenced by medical history and screening\n* For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional month after the end of the study\n* Still menstruating regularly (defined at least one period every 60 days)\n* Agreement to adhere to Lifestyle Considerations throughout study duration\n\nExclusion Criteria:\n\n* Pregnant, trying to conceive, or breastfeeding\n* Hysterectomy, uterine ablation, or related procedure\n* Amenorrhea\n* Consumes \\> 8 alcoholic beverages in an average week\n* Currently consumes an ashwagandha supplement or has consumed one regularly (defined as 1x week or more often) within the past 24 months\n* Consumes any hormonal therapies or menopause-related supplements intended to improve symptoms in any way\n* Current or recent (within 60 days) history of taking thyroid medications, hypertensive drugs, CNS depressants, diabetic medications, benzodiazepines, or immunosuppressants\n* Any liver, kidney, hormonal, or cardiovascular disorder\n* Known allergic reactions to any components of the intervention\n* Recent dramatic weight changes (10% change in body weight in the last 6 months)\n* Introducing a new investigational drug or other intervention within 60 days before the start of the study\n* Any change to diet or lifestyle within 60 days before the start of the study (defined as introducing any new exercise activity, joining a gym, starting a new routine, moving to a new home, adjusting dietary habits (e.g. vegetarian, paleo, etc) or discontinuing any habits or diets.\n* Any health or medical condition which, in the primary investigators opinion, may interfere with the conduct of the study","FEMALE","40 Years","55 Years",{"count":19,"type":20},90,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to evaluate the efficacy of two proprietary ashwagandha extracts on symptoms of menopause and hormone levels, as compared to a placebo.",[26,27],"Menopausal Hot Flashes","Menopausal Women",[29],"ashwagandha","NOT_YET_RECRUITING","2025-09-29",{"date":33,"type":34},"2025-10-07","ACTUAL",{"date":36,"type":20},"2025-10-01",{"date":38,"type":20},"2026-03-30",{"name":40,"class":41},"Nutraceuticals Research Institute","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":16,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":42},"100586742","absorption-and-tolerability-of-injectable-administration-of-niagen-as-compared-to-nad-100586742","NCT06919328","Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+","Absorption and Tolerability of Injectable Administration of Niagen®+, Nicotinamide Riboside Chloride, a Specialized Form of Vitamin B3, as Compared to NAD+: a Double Blinded, Randomized, Controlled Clinical Trial","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness and demonstrated ability to comply with all study procedures, as well as availability for the duration of the study\n* Lives within 100 miles of the NRI study site\n* Any gender, aged 40-65, inclusive\n* Good general health as evidenced by medical history\n* BMI 25-34.9 kg\u002Fm2\n* Sedentary behavior (defined as \\\u003C20 minutes per day or 100 minutes per week of moderate to vigorous exercise)\n* Demonstrated fatigue (Fatigue Assessment Scale) defined as a below-average score\n* For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional month after the end of the study\n* Agreement to adhere to Lifestyle Considerations throughout study duration\n\nExclusion Criteria:\n\n* Current diagnosis of any seizure disorder, diabetes or insulin resistance, any kidney or liver disorder, heart disease, anemia, cancer, or Parkinson's disease\n* ANY chronic illness (pre-disease state acceptable)\n* Out of range phosphate levels at baseline\n* BMI less than 25 or greater than or equal to 35\n* Pregnancy, trying to conceive, or breastfeeding\n* Known allergic reactions to any components of the intervention or related compounds, including any form of B3\n* Positive COVID-19 test within 30 days of the study period\n* Recent dramatic weight changes (10% change in body weight in the last 6 months)\n* Existing usage of a NAD+ or NAD precursor supplement in any form (oral, nasal, patch, or injection\u002FIV administration), including a B-complex supplement, within 60 days of the study, not including multivitamins.\n* Introducing a new medication, supplement, investigational drug, or other intervention (including lifestyle changes) within 60 days of the start of the study.",true,"ALL","65 Years",{"count":54,"type":20},70,[23],"This study evaluates the subjective effects of injection administration of NR on healthy adult populations.",[58],"Healthy Aging",[60],"NAD+","RECRUITING","2025-04-07",{"date":64,"type":34},"2025-04-09",{"date":66,"type":34},"2024-10-31",{"date":68,"type":20},"2025-06-30",{"name":40,"class":41},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":50,"sex":15,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":42},"100577099","effects-of-ashwagandha-extract-on-stress-levels-100577099","NCT06793891","Effects of Ashwagandha Extract on Stress Levels","The Effectiveness of a Proprietary Ashwagandha Extract on Stress Reduction: A Three-Arm Randomized, Double-Blinded, Placebo Controlled Clinical Trial","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness and demonstrated ability to comply with all study procedures, as well as availability for the duration of the study\n* Self reported high stress\n* Baseline score of above-average stress levels on the NRI-SS\n* Biological sex of woman; gender identification of female\n* Aged 30 to 59, inclusive\n* Good general health as evidenced by medical history and screening\n* For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional month after the end of the study\n* Agreement to adhere to Lifestyle Considerations throughout study duration\n\nExclusion Criteria:\n\n* Pregnancy, trying to conceive, or breastfeeding\n* Currently smokes or vapes (i.e., tobacco, flavored items, marijuana, etc.) or has in the past year\n* Consumes \\> 8 alcoholic beverages in an average week\n* Is a primary caretaker for a child younger than 18 months of age\n* Currently consumes an ashwagandha supplement or has consumed one regularly (defined as 1x week or more often) within the past 24 months\n* Consumes any stress aid, medication, diet, or supplement intended to improve stress in any way\n* Current or recent (within 60 days) history of taking thyroid medications, hypertensive drugs, CNS depressants, diabetic medications, benzodiazepines, or immunosuppressants\n* Any liver or kidney disorder\n* Known allergic reactions to any components of the intervention\n* Positive COVID-19 test within 30 days of the study period\n* Recent dramatic weight changes (10% change in body weight in the last 6 months)\n* Introducing a new investigational drug or other intervention within 60 days before the start of the study\n* Introducing a new lifestyle stress-reduction aid (i.e. physical activity, yoga, etc) within 60 days before the start of the study","30 Years","59 Years",{"count":80,"type":20},60,[23],"The purpose of this study is to evaluate the efficacy of two proprietary ashwagandha extracts on stress levels, with secondary outcomes of cognition, energy, and sleep, as compared to a placebo.",[84],"Stress",[86,87,88,89,90],"energy","fatigue","cognition","nutraceuticals","Ashwagandha","2025-01-21",{"date":93,"type":34},"2025-01-27",{"date":95,"type":34},"2024-10-21",{"date":97,"type":20},"2025-04-30",{"name":40,"class":41},""]